File Download

There are no files associated with this item.

Supplementary

Conference Paper: A Novel Oral Chemoprophylactic Agent for Venous Thromboembolism after Total Knee Arthroplasty — Is It Safe?

TitleA Novel Oral Chemoprophylactic Agent for Venous Thromboembolism after Total Knee Arthroplasty — Is It Safe?
Authors
Issue Date2013
PublisherHong Kong Academy of Medicine Press.
Citation
The 33rd Annual Congress of the Hong Kong Orthopaedic Association (HKOA), Hong Kong, China, 23-24 November 2013. In the Abstracts of the 33rd Annual Congress of the Hong Kong Orthopaedic Association (HKOA), 2013, p. 76, abstract no. 9.3 How to Cite?
AbstractIntroduction: Venous thromboembolism and postoperative wound drainage and subsequent infection are both serious complications after primary total knee arthroplasty (TKA). The balance between bleeding and clotting is a dilemma. Newer agents include direct factor Xa inhibitor is quoted to have superior efficacy to prevent deep vein thrombosis compared with low-molecular-weight heparin without increasing side-effect of major blood loss. This study aimed to examine the safety profile of a novel factor Xa inhibitor (Apixaban) used in Chinese patients. Materials and Methods: A total of 40 consecutive patients (8 male and 32 female) with a mean age of 73.6 (range, 54- 84) years requiring unilateral TKA were recruited. Twenty patients received a course of 2-week 2.5 mg Apixaban twice daily as chemoprophylaxis. The wound condition, soaking of gauze, swelling of the limb, perioperative haemoglobin and haematocrit, renal function, C-reactive protein, thromboembolism, and bleeding complication were documented. Another 20 patients undergoing a course of 2-week 300 mg aspirin daily as chemoprophylaxis were compared. Results: Preoperative mechanical alignment of both groups was comparable. The drain output, frequency of wound dressing, and soaking of dressing between the groups were comparable. There was neither thromboembolism nor bleeding complications. Both groups showed a sustained and comparable increase in haemoglobin and haematocrit and stable renal function. There was no surgical site infection. Discussion and Conclusion: The early experience using Apixaban as chemoprophylaxis in TKA is safe. Longer period of use of the drug is required to monitor its efficacy and safety.
DescriptionConference Theme: Defying the Aging Spine
Concurrent Free Papers 9: Hips and Knees II
Persistent Identifierhttp://hdl.handle.net/10722/204335

 

DC FieldValueLanguage
dc.contributor.authorNg, FYen_US
dc.contributor.authorFu, CHHen_US
dc.contributor.authorYan, CHen_US
dc.contributor.authorChan, PKen_US
dc.contributor.authorChiu, PKYen_US
dc.date.accessioned2014-09-19T22:41:15Z-
dc.date.available2014-09-19T22:41:15Z-
dc.date.issued2013en_US
dc.identifier.citationThe 33rd Annual Congress of the Hong Kong Orthopaedic Association (HKOA), Hong Kong, China, 23-24 November 2013. In the Abstracts of the 33rd Annual Congress of the Hong Kong Orthopaedic Association (HKOA), 2013, p. 76, abstract no. 9.3en_US
dc.identifier.urihttp://hdl.handle.net/10722/204335-
dc.descriptionConference Theme: Defying the Aging Spine-
dc.descriptionConcurrent Free Papers 9: Hips and Knees II-
dc.description.abstractIntroduction: Venous thromboembolism and postoperative wound drainage and subsequent infection are both serious complications after primary total knee arthroplasty (TKA). The balance between bleeding and clotting is a dilemma. Newer agents include direct factor Xa inhibitor is quoted to have superior efficacy to prevent deep vein thrombosis compared with low-molecular-weight heparin without increasing side-effect of major blood loss. This study aimed to examine the safety profile of a novel factor Xa inhibitor (Apixaban) used in Chinese patients. Materials and Methods: A total of 40 consecutive patients (8 male and 32 female) with a mean age of 73.6 (range, 54- 84) years requiring unilateral TKA were recruited. Twenty patients received a course of 2-week 2.5 mg Apixaban twice daily as chemoprophylaxis. The wound condition, soaking of gauze, swelling of the limb, perioperative haemoglobin and haematocrit, renal function, C-reactive protein, thromboembolism, and bleeding complication were documented. Another 20 patients undergoing a course of 2-week 300 mg aspirin daily as chemoprophylaxis were compared. Results: Preoperative mechanical alignment of both groups was comparable. The drain output, frequency of wound dressing, and soaking of dressing between the groups were comparable. There was neither thromboembolism nor bleeding complications. Both groups showed a sustained and comparable increase in haemoglobin and haematocrit and stable renal function. There was no surgical site infection. Discussion and Conclusion: The early experience using Apixaban as chemoprophylaxis in TKA is safe. Longer period of use of the drug is required to monitor its efficacy and safety.-
dc.languageengen_US
dc.publisherHong Kong Academy of Medicine Press.-
dc.relation.ispartofAnnual Congress of the Hong Kong Orthopaedic Association (HKOA)en_US
dc.rightsAnnual Congress of the Hong Kong Orthopaedic Association (HKOA). Copyright © Hong Kong Academy of Medicine Press.-
dc.titleA Novel Oral Chemoprophylactic Agent for Venous Thromboembolism after Total Knee Arthroplasty — Is It Safe?en_US
dc.typeConference_Paperen_US
dc.identifier.emailNg, FY: fyng@hkucc.hku.hken_US
dc.identifier.emailFu, CHH: drhfu@hku.hken_US
dc.identifier.emailYan, CH: yanchoi@hku.hken_US
dc.identifier.emailChan, PK: cpk464@hku.hken_US
dc.identifier.emailChiu, PKY: pkychiu@hkucc.hku.hken_US
dc.identifier.authorityYan, CH=rp00303en_US
dc.identifier.authorityChiu, PKY=rp00379en_US
dc.identifier.hkuros235781en_US
dc.identifier.hkuros240365-
dc.identifier.spage76, abstract no. 9.3en_US
dc.identifier.epage76, abstract no. 9.3en_US
dc.publisher.placeHong Kong, China-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats